Emery-Dreifuss Muscular Dystrophy Overview
Learn About Emery-Dreifuss Muscular Dystrophy
Emery-Dreifuss muscular dystrophy is a condition that primarily affects muscles used for movement (skeletal muscles) and the heart (cardiac muscle). Among the earliest features of this disorder are joint deformities called contractures. Contractures restrict the movement of certain joints, most often the elbows, ankles, and neck, and usually become noticeable in early childhood. Most affected individuals also experience muscle weakness and wasting that worsen slowly over time, beginning in muscles of the upper arms and lower legs and later also affecting muscles in the shoulders and hips.
Mutations in several genes, including EMD, FHL1, and LMNA, can cause Emery-Dreifuss muscular dystrophy. Mutations in the EMD gene or, less commonly, in the FHL1 gene cause the X-linked type of the condition. Mutations in the LMNA gene cause both the autosomal dominant and autosomal recessive types of the condition.
The overall prevalence of Emery-Dreifuss muscular dystrophy is unknown. The X-linked type of this disorder affects an estimated 1 in 100,000 people. The prevalence of the autosomal dominant type is unknown, although it appears to be more common than the X-linked type. The autosomal recessive type appears to be very rare; only a few cases have been reported worldwide.
Emery-Dreifuss muscular dystrophy can have several different patterns of inheritance. When the condition is caused by mutations in the EMD or FHL1 gene, it is inherited in an X-linked recessive pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes in each cell. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. Males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Bronson Methodist Hospital
Michelle Crooks is a Neurologist in Kalamazoo, Michigan. Dr. Crooks and is rated as an Experienced provider by MediFind in the treatment of Emery-Dreifuss Muscular Dystrophy. Her top areas of expertise are Myasthenia Gravis, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Supranuclear Ocular Palsy. Dr. Crooks is currently accepting new patients.
Spectrum Health Primary Care Partners
Matthew Ebright is a Neurologist in Grand Rapids, Michigan. Dr. Ebright has been practicing medicine for over 12 years and is rated as an Experienced provider by MediFind in the treatment of Emery-Dreifuss Muscular Dystrophy. His top areas of expertise are Inclusion Body Myositis, Myasthenia Gravis, Multiple Sclerosis (MS), and Relapsing Multiple Sclerosis (RMS). Dr. Ebright is currently accepting new patients.
Memorial Hospital
Dustin Nowacek is a Neurologist and a Neuroradiologist in Perry, Michigan. Dr. Nowacek and is rated as a Distinguished provider by MediFind in the treatment of Emery-Dreifuss Muscular Dystrophy. His top areas of expertise are Dysferlinopathy, Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Spinal Muscular Atrophy (SMA). Dr. Nowacek is currently accepting new patients.
Summary: Mutations in the LMNA gene, which codes for lamins A and C, proteins of the nuclear lamina, are responsible for a wide spectrum of pathologies, including a group specifically affecting striated skeletal and cardiac muscles, with cardiac involvement being life-threatening. At the skeletal muscle level, a wide phenotypic spectrum has been described, ranging from severe forms of congenital muscular d...
Summary: Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the description of the clinical and genetic spectrum of these disea...
Published Date: June 01, 2017
Published By: National Institutes of Health